ArticleBMC cancer2025
Gene mutation in cancer patients with diabetes: a real-world retrospective cohort study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Micro- and Nanoplastics and Functional Nutrients in Human Health: Epigenetic Mechanisms and Cellular Resilience Signaling in Brain Insulin Resistance and the Risk of Alzheimer's Disease.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDiabetes mellitus (DM) exhibits a strong association with tumorigenesis, yet its impact on tumor gene mutations remains poorly understood. Consequently, the present study was conducted to delve into the influence of DM on tumor gene mutations.
methodsThis study enrolled 397 lung adenocarcinoma (ADC), 312 colorectal cancer (CRC), and 210 breast cancer (BC) patients between 2016 and 2024. All participants underwent next-generation sequencing (NGS) to detect tumor mutation genes (including point mutations, insertion, deletion, inversion, and duplication) and had their clinical characteristics evaluated. Linear regression analysis and Spearman correlation analysis were carried out to evaluate the association between DM and tumor gene mutations.
resultsHerein, tumor patients with DM exhibited significantly lower genetic mutation rates than non-DM individuals across all analyzed cancer types: ADC (49.76% vs. 66.15%, p < 0.001), CRC (28.95% vs. 45.96%, p = 0.003), and BC (34.31% vs. 48.15%, p = 0.042). A history of smoking (OR = 5.250, 95% CI, 1.858-14.835, p = 0.002), clinical stage II (OR = 14.495, 95% CI: 4.860-43.227, p = 0.001), and stage IV (OR = 21.022, 95% CI: 3.753-117.761, p = 0.001) were associated with ADC gene mutations. For CRC, clinical stage II trended toward an association with gene mutations (OR = 4.021, 95%CI, 0.966-16.745, p = 0.056). In BC, WBC count were negatively correlated with BC gene mutations (OR = 0.675, 95%CI, 0.461-0.987, p = 0.043). Notably, DM was independently associated with a reduced likelihood of tumor gene mutations across all cancer types analyzed.
conclusionThis study suggests that DM may lower the likelihood of genetic mutations in tumors, however, tumor gene mutations are influenced by multiple factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.